MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Five Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease

L. Timmermann, R. Jain, N. Van Dyck, L. Chen, T. Brücke, F. Siejo, E. Suarez-San Martin, V. Visser-Vandewalle, M. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Köln, Germany)

Meeting: 2018 International Congress

Abstract Number: 413

Keywords: Deep brain stimulation (DBS), Neurostimulation, Parkinsonism

Session Information

Date: Saturday, October 6, 2018

Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: To evaluate the long term follow up of patients in the VANTAGE Study that employed a Deep Brain Stimulation (DBS) system with multiple independent current control (MICC) in the management of symptoms of Parkinson’s disease.

Background: We postulated that a multiple source, constant current DBS device (CE marked) permitting a well defined distribution of current would lead to motor improvement in patients with Parkinson’s disease (PD). The study demonstrated highly significant improved motor function (p <0.0001) as assessed by UPDRS III "meds off" at 6 months post first lead implant as compared with Baseline "meds off," thereby successfully achieving the study primary endpoint. Here we present the five year, long term results.

Methods: VANTAGE is a prospective, multicenter, nonrandomized, open label trial sponsored by Boston Scientific. Forty subjects with idiopathic PD were implanted bilaterally with a DBS system (Vercise, Boston Scientific) targeting the subthalamic nucleus and followed up to five years post lead placement. Assessments included UPDRS III scores in the meds off condition, quality of life such as Parkinson’s Disease Questionnaire (PDQ39), Modified Schwab and England (SE), etc. Adverse events were collected.

Results: At four years post lead placement, quality of life as assessed by PDQ39, SE continued to show improvement as compared to baseline. Additionally, the usage of antiparkinsonian medications continued to show a similar trend as reported earlier. This report will present the long term motor outcomes and quality of life results at 5 years post lead placement.

Conclusions: The collected outcomes from the VANTAGE clinical trial will inform clinicians on use of this system, and its flexibility to manage symptoms of idiopathic PD.

To cite this abstract in AMA style:

L. Timmermann, R. Jain, N. Van Dyck, L. Chen, T. Brücke, F. Siejo, E. Suarez-San Martin, V. Visser-Vandewalle, M. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch. Five Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/five-year-outcomes-of-a-prospective-multicenter-trial-evaluating-deep-brain-stimulation-with-a-new-multiple-source-constant-current-rechargeable-system-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/five-year-outcomes-of-a-prospective-multicenter-trial-evaluating-deep-brain-stimulation-with-a-new-multiple-source-constant-current-rechargeable-system-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley